Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
advm-022 save search
El Pollo Loco Names Jill Adams New Chief Marketing Officer
Published: 2023-10-05 (Crawled : 13:30) - globenewswire.com
BOX 4 | $26.67 0.76% -0.0% 1.5M
|
Technology Services
|
| O: -0.2%
H: 1.23%
C: 1.05%
LOCO | $8.32 -0.12% -0.12% 210K
|
Consumer Services
|
| O: 0.11%
H: 0.62%
C: -1.81%
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
Published: 2022-11-04 (Crawled : 17:00) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 1.32%
H: 14.6%
C: -3.5%
advm-022 trial positive injection results study
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
Published: 2022-09-30 (Crawled : 21:00) - globenewswire.com
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
| Email alert
Add to watchlist
advm-022 injection study
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Published: 2022-09-08 (Crawled : 16:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
Published: 2022-09-08 (Crawled : 14:20) - biospace.com/
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.47%
C: 0.35%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.69%
H: 2.52%
C: 2.52%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.49%
C: 0.27%
otezla positive
AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
Published: 2022-08-30 (Crawled : 14:00) - biospace.com/
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.76%
H: 0.37%
C: -1.8%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.21%
H: 0.18%
C: -0.32%
positive
AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.11%
H: 0.38%
C: -0.36%
skin
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
Published: 2022-07-15 (Crawled : 13:00) - globenewswire.com
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 1.14%
H: 0.56%
C: -6.78%
advm-022 injection study
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
Published: 2022-07-06 (Crawled : 00:00) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 0.86%
H: 5.13%
C: 5.13%
advm-022 trial phase 2
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
Published: 2022-06-24 (Crawled : 12:20) - globenewswire.com
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -0.93%
H: 3.74%
C: -0.93%
advm-022 designation granted
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
Published: 2022-06-09 (Crawled : 14:00) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -0.92%
H: 2.78%
C: -0.93%
advm-022 injection
Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
Published: 2022-06-04 (Crawled : 16:20) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
bmf-219 treatment preclinical diabetes potential pre-clinical
Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022
Published: 2022-06-01 (Crawled : 14:00) - biospace.com/
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -0.36%
H: 1.65%
C: -18.65%
bmf-219 preclinical diabetic pre-clinical
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
Published: 2022-05-01 (Crawled : 20:20) - globenewswire.com
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -0.89%
H: 4.05%
C: 0.0%
advm-022 trial
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
Published: 2021-12-21 (Crawled : 15:30) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 2.69%
H: 0.0%
C: -2.09%
advm-022 biotech iot milestone
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
Published: 2021-10-09 (Crawled : 16:20) - globenewswire.com
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
| Email alert
Add to watchlist
retina
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
injection
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
Published: 2021-09-27 (Crawled : 13:15) - globenewswire.com
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 1.35%
H: 8.85%
C: 4.87%
clinical trials trials trial conference
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
Published: 2021-07-22 (Crawled : 21:00) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -0.63%
H: 0.96%
C: -2.24%
trial macular diabetic diabetes
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.